8-K current report · filed Nov 12, 2026

Absci Corp (ABSI) 8-K Current Report: November 12, 2026

Item 2.02Item 8.01Item EX-99.2Item EX-99.1ABSI overview

Short answer

Absci Corp (ABSI) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.1 (Exhibit EX-99.1). Third-quarter fiscal 2026 results announced for period ended September 30, 2026.

Absci Corp 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Third-quarter fiscal 2026 results announced for period ended September 30, 2026
  • Full financial results and management commentary available in Exhibit 99.1
  • Release provides investors the quarter’s latest operating and financial update

Item 8.01 · Other Events

  • Absci released an investor presentation on November 12, 2026 covering internal pipeline program updates
  • Pipeline disclosures may affect investor views on development priorities, clinical progress and future catalysts
  • Full program details are in Exhibit 99.2 and the company’s News & Events webpage

Item EX-99.1 · Exhibit EX-99.1

  • ABS-201 HEADLINE trial on track, with 13-week pattern hair-loss proof-of-concept data expected December 2026 and full 26-week data early 2027
  • Planned Phase 2 STORYLINE endometriosis trial targets approximately 150 patients across approximately 10 countries, with initiation anticipated mid-2027
  • Q3 revenue $0.3M versus $0.4M, while R&D rose to $23.6M from $19.2M, reflecting heavier ABS-201 development investment
  • Net loss widened to $33.3M from $28.7M, with loss per share improving to $(0.19) from $(0.20) on higher share count
  • Cash, equivalents and marketable securities $173.7M at September 30, 2026, expected to fund operations into the second half of 2028

Item EX-99.2 · Exhibit EX-99.2

  • Corporate presentation highlights ABS-201’s Ph1/2a PHL program, with interim proof-of-concept readout expected December 2026
  • Interim SAD data showed favorable blinded safety and tolerability, with half-life of at least 65 days
  • ABS-201 targets an estimated 80M U.S. PHL patients and a potential global market exceeding $40B, based on company-commissioned research
  • Endometriosis expansion targets roughly 9M U.S. patients, with Phase 2 initiation expected mid-2027 and potential peak sales above $4.5B
  • Pipeline includes ABS-101 for IBD and multiple partnering-ready programs, supporting potential non-ABS-201 collaboration catalysts

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Absci Corp 8-K filings

Get the next ABSI 8-K as it lands

Follow ABSI for push alerts, or ask the research agent what this filing means.